Table 4.
Time of escape from HI placement (months, average±SD) | LH (mIU/mL) | T (ng/dL) | Estradiol (pg/mL) | GAHT | HI outcome | Escape biochemical/clinical | |
---|---|---|---|---|---|---|---|
Group A (n=4) | 33.3±21.6 | ||||||
A1 | 27 | n/a | n/a | — | Replaced | Clinical (breast enlargement) | |
A2 | 24 | n/a | 104 | — | Replaced | Biochemical | |
A3 | 65 | 2.2 | 390 | 138 | 2 mg estradiol oral | In place, added Lupron | Biochemical and clinical (testicular enlargement, voice change) |
A4 | 7 | 0.93 | 20 | — | Replaced (29 months) | Biochemical | |
17 | 1.15 | 52 | — | ||||
21 | 0.9 | 34 | — | ||||
25 | 1.05 | 16 | 17 | 1.5 mg estradiol oral | |||
Group B (n=4) | 27.5±12.2 | ||||||
B1 | 28 | n/a | 51 | 75 mcg weekly transdermal estradiol | Replaced | Biochemical | |
B2 | 44 | 64 | 106 | 4 mg estradiol oral | In place, Increased estradiol | Biochemical | |
B3 | 23 | 0.09 | 182 | 3 | 12.5 mg SC-T bi-weekly | Replaced | Clinical (spotting) |
B4 | 15 | 0.97 | 80 | — | In place, started estradiol | Biochemical | |
All subjects (n=8) Average, months±SD |
30.4±16.5 |
n/a, not available; SC-T, subcutaneous testosterone.